AR071069A1 - Derivados sustituidos de pirazol y su uso para la prevencion o el tratamiento de cancer - Google Patents

Derivados sustituidos de pirazol y su uso para la prevencion o el tratamiento de cancer

Info

Publication number
AR071069A1
AR071069A1 ARP090101059A ARP090101059A AR071069A1 AR 071069 A1 AR071069 A1 AR 071069A1 AR P090101059 A ARP090101059 A AR P090101059A AR P090101059 A ARP090101059 A AR P090101059A AR 071069 A1 AR071069 A1 AR 071069A1
Authority
AR
Argentina
Prior art keywords
group
atom
conh
formula
hydrogen atom
Prior art date
Application number
ARP090101059A
Other languages
English (en)
Inventor
Mitsuhiro Ito
Naoki Tomita
Tomohiko Suzaki
Tomohiro Kaku
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR071069A1 publication Critical patent/AR071069A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado por la formula (1) en donde R1' es (1) un átomo de hidrogeno, (2) un grupo a través de un átomo de carbono, (3) un grupo a través de un átomo de N; (4) un grupo a través de un átomo de oxígeno o (5) un grupo a través de un átomo de azufre; R2' es un grupo de anillo aromático que opcionalmente tiene sustituyentes; R3' es (1) un átomo de hidrogeno, (2) un grupo a través de un átomo de carbono, (3) un grupo a través de un átomo de nitrogeno, (4) un grupo a través de un átomo de oxígeno o (5) un grupo a través de un átomo de azufre; R4' es un grupo de cianofenilo que opcionalmente tiene sustituyentes; X' es (1) -Y'-CR5'R6'-Z'- en donde R5' y R6' son iguales o diferentes y cada uno es un átomo de hidrogeno, un grupo a través de un átomo de carbono, un grupo a través de un átomo de nitrogeno, un grupo a través de un átomo de oxígeno o un grupo a través de un átomo de azufre o -CR5'R6'- es -C(alquilideno)-; Y' es un enlace, -COCO-, -CONH-, -COCONH- u -O-; y Z' es un enlace, -CH2-, -CONH-, -O-, -OCH2-, -S-, -SO-, -SO2-, -CON(C6H5)- o un compuesto de formula (2), (2) -CO(CONH)n- en donde n es 0 o 1, (3) -NHCO-, (4) -CONH-, (5) -O-, (6) -CH=CH- o (7) -O(alquilen C1-3)O-; excluyendo los compuestos de formulas (3), un compuesto representado por la formula (4) en donde uno de Rd, Rd1 y Rd2 es un grupo ciano y los otros dos grupos son iguales o diferentes y cada uno es un átomo de hidrogeno, un átomo de cloro o un grupo metilo y un compuesto representado por la formula (5) en donde Re1 es un grupo metilo, un grupo etilo o un grupo metoximetilo, uno de Re2 y Re3 es un grupo ciano y el otro es un átomo de hidrogeno, o una de sus sales. Reivindicacion 2: Un compuesto caracterizado por la formula (6) en donde R1 es (1) un átomo de hidrogeno, (2) un grupo a través de un átomo de carbono, (3) un grupo a través de un átomo de nitrogeno, (4) un grupo a través de un átomo de oxígeno o (5) un grupo a través de un átomo de azufre; R2 es un grupo de anillo aromático que opcionalmente tiene sustituyentes; R3 es (1) un átomo de hidrogeno, (2) un grupo a través de un átomo de carbono, (3) un grupo a través de un átomo de nitrogeno, (4) un grupo a través de un átomo de oxígeno o (5) un grupo a través de un átomo de azufre; R4 es un grupo de cianofenilo que opcionalmente tiene sustituyentes; X es (1) -Y-CR5R6-Z- en donde R5 y R6 son iguales o diferentes y cada uno es un átomo de hidrogeno, un grupo a través de un átomo de carbono, un grupo a través de un átomo de nitrogeno, un grupo a través de un átomo de oxígeno o un grupo a través de un átomo de azufre o -CR5R6- es -C(alquilideno)-; Y es un enlace, -COCO-, -CONH-, -COCONH- u -O-; y Z es un enlace, -CH2-, -CONH-, -O-, -OCH2-, -S-, -SO-, o -SO2-, (2) -CO(CONH)n- en donde n es 0 o 1, (3) -NHCO-, (4) -CONH-, (5) -O- o (6) -CH=CH-; excluyendo los siguientes compuestos de formulas (3); un compuesto representado por la formula (4) en donde uno de Rd, Rd1 y Rd2 es un grupo ciano y los otros dos grupos son iguales o diferentes y cada uno es un átomo de hidrogeno, un átomo de cloro o un grupo metilo y un compuesto representado por la formula (5) en donde Re1 es un grupo metilo, un grupo etilo o un grupo metoximetilo, uno de Re2 y Re3 es un grupo ciano y el otro es un átomo de hidrogeno, o una de sus sales.
ARP090101059A 2008-03-26 2009-03-25 Derivados sustituidos de pirazol y su uso para la prevencion o el tratamiento de cancer AR071069A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008082029 2008-03-26

Publications (1)

Publication Number Publication Date
AR071069A1 true AR071069A1 (es) 2010-05-26

Family

ID=40934870

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101059A AR071069A1 (es) 2008-03-26 2009-03-25 Derivados sustituidos de pirazol y su uso para la prevencion o el tratamiento de cancer

Country Status (6)

Country Link
US (1) US20090270361A1 (es)
AR (1) AR071069A1 (es)
PE (1) PE20091653A1 (es)
TW (1) TW200944506A (es)
UY (1) UY31736A (es)
WO (1) WO2009119880A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR068813A1 (es) * 2007-08-30 2009-12-09 Takeda Pharmaceutical Derivados de pirazol sustituidos como antagonistas del receptor de androgenos (ar), un agente farmaceutico que los comprende y su uso en el tratamiento del cancer de prostata
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9000154B2 (en) 2010-10-19 2015-04-07 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JP6240677B2 (ja) * 2012-11-13 2017-11-29 バイエル・クロップサイエンス・アクチェンゲゼルシャフト カルボキサミド類を製造する方法
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
EP3154947B1 (en) * 2014-06-11 2018-03-28 Bayer CropScience Aktiengesellschaft Process for preparing 3,5-bis(haloalkyl)pyrazoles via acylation of ketimines
WO2016202935A1 (en) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
CN108137549B (zh) 2015-08-05 2021-07-20 百时美施贵宝公司 取代的甘氨酸衍生的fxia抑制剂
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2022013728A1 (en) * 2020-07-14 2022-01-20 Chong Kun Dang Pharmaceutical Corp. Novel compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
KR102685058B1 (ko) 2020-09-02 2024-07-15 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물
CN113861186B (zh) * 2021-09-10 2023-08-25 浙江师范大学 基于异恶唑取代苯甲酰胺类衍生物及抗前列腺癌药物应用
WO2024033293A1 (en) * 2022-08-08 2024-02-15 Italfarmaco S.P.A. Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors
CN116496218B (zh) * 2023-04-27 2025-07-22 河南大学 一种n-乙烯基吡唑类化合物的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4116090A1 (de) * 1991-05-17 1992-11-19 Basf Ag (alpha)-phenylacrylsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von schaedlingen und schadpilzen
DE4305502A1 (de) * 1993-02-23 1994-08-25 Basf Ag Ortho-substituierte 2-Methoxyiminophenylessigsäuremethylamide
GB9519787D0 (en) * 1995-09-28 1995-11-29 Sandoz Ltd Organic compounds
GB2380171B (en) * 2001-09-27 2003-08-06 Red Lan Stroller with shock absorbing units
WO2003057669A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Antagonistes du recepteur androgene
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
JP5020073B2 (ja) * 2004-06-18 2012-09-05 ミレニアム ファーマシューティカルズ インク． 第Ｘａ因子阻害剤
TW200628446A (en) * 2004-12-14 2006-08-16 Takeda Pharmaceuticals Co Substituted pyrrole derivative
EP1874732A1 (en) * 2005-04-20 2008-01-09 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
AU2008284662B2 (en) * 2007-08-07 2013-07-25 Takeda Pharmaceutical Company Limited Pyrrolidin-2 -one derivatives as androgen receptor modulator

Also Published As

Publication number Publication date
TW200944506A (en) 2009-11-01
PE20091653A1 (es) 2009-11-14
WO2009119880A1 (en) 2009-10-01
UY31736A (es) 2009-11-10
US20090270361A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
AR068813A1 (es) Derivados de pirazol sustituidos como antagonistas del receptor de androgenos (ar), un agente farmaceutico que los comprende y su uso en el tratamiento del cancer de prostata
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
PE20061335A1 (es) Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
TNSN08407A1 (en) Organic compounds
PE20140976A1 (es) Inhibidores de benzodioxano de la producion de leucotrieno
CO6241121A2 (es) Derivados de azapeptidps
PE20070519A1 (es) Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
CY1117165T1 (el) Καινοφανεις τρικυκλικες ενωσεις
MX420195B (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
CO6190521A2 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta -9 desaturasa
DK2279187T3 (da) Spirocykliske derivater som histondeacetylaseinhibitorer
ECSP12012056A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
ECSP10010415A (es) Compuestos novedosos que son inhibidores de erk
ES2662444T3 (es) Derivado de piridina
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
CO5700757A2 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
AR061419A1 (es) Compuestos de piridil amida sustituidos como moduladores del receptor de histamida h3
TW200639158A (en) New compounds with therapeutic effect
AR072793A1 (es) Compuestos de aril isoxazol con actividades antitumorales
AR064358A1 (es) Procedimiento para la preparacion de derivados benzimida piperacinilo y diazepanilo
MX2016007991A (es) Derivados antibacteriales de 1h-indazol y 1h-indol.

Legal Events

Date Code Title Description
FB Suspension of granting procedure